Table 3 Baseline characteristics of weighted cohort

Count (W)

1839

1842

Age at heart failure: Mean (SD)

64.67 (14.72)

64.73 (14.60)

Female Sex at Birth: % (W)

39.7% (730)

39.5% (728)

Race: % (W)

 Black

17.1% (314)

17.0% (314)

 Other^a

2.3% (42)

2.3% (43)

 White

80.7% (1484)

80.6% (1486)

Albumin: Mean (SD)

4.00 (0.45)

4.0 (0.46)

Systolic Blood Pressure: Mean (SD)

133.40 (21.23)

133.27 (21.17)

Diastolic Blood Pressure: Mean (SD)

76.05 (13.46)

76.06 (13.68)

Body Mass Index: Mean (SD)

29.37 (7.08)

29.39 (7.11)

Estimated GFR: Mean (SD)

83.78 (28.91)

83.44 (28.78)

Atrial Fibrillation: % (W)

13.7% (252)

13.6% (249)

Anemia: % (W)

7.3% (134)

7.2% (132)

COPD: % (W)

15.6% (286)

15.4% (283)

Coronary Artery Disease: % (W)

33.9% (623)

34.0% (627)

Diabetes: % (W)

30.2% (555)

30.3% (558)

Hypertension: % (W)

60.4% (1112)

60.4% (1113)

Liver Disease: % (W)

4.4% (81)

4.4% (81)

Myocardial Infarction: % (W)

9.8% (181)

9.8% (181)

Peripheral Artery Disease: % (W)

8.1% (149)

8.1% (149)

Rheumatic Disease: % (W)

6.0% (111)

6.0% (111)

Alcohol Abuse: % (W)

3.4% (63)

3.4% (63)

Cancer: % (W)

23.4% (430)

23.3% (429)

HIV: % (W)

2.1% (38)

2.1% (39)

Dyslipidemia: % (W)

70.0% (1281)

70.0% (1285)

CT Scan with Contrast: % (W)

1.7% (32)

1.7% (31)

Ace Inhibitors: % (W)

19.0% (348)

19.1% (352)

Alpha Blockers: % (W)

1.2% (22)

1.2% (23)

Beta Blockers: % (W)

20.0% (359)

19.7% (364)

Loop Diuretics: % (W)

7.5% (138)

7.6% (140)

Mineralocorticoid Antagonists: % (W)

1.6% (30)

1.7% (31)

Nitrates: % (W)

7.2% (133)

7.2% (132)

Non-Loop Diuretics: % (W)

14.3% (263)

14.3% (264)

Statins: % (W)

24.5% (451)

24.7% (455)

NSAIDS: % (W)

17.1% (314)

17.0% (213)

Calcium Channel Blockers: % (W)

15.6% (287)

15.7% (289)

Angiotensin II Receptor Antagonists: % (W)

9.9% (182)

9.9% (183)

Insulin: % (W)

6.1% (112)

6.1% (112)

Metformin: % (W)

8.9% (163)

8.9% (164)

Other Diabetes Medications: % (W)

7.8% (144)

7.9% (146)